Mobocertinib Succinate Patent Expiration
Mobocertinib Succinate is Used for treating non-small cell lung cancer patients with EGFR exon 20 insertion mutations whose disease has progressed after platinum-based chemotherapy. It was first introduced by Takeda Pharmaceuticals Usa Inc
Mobocertinib Succinate Patents
Given below is the list of patents protecting Mobocertinib Succinate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Exkivity | US10227342 | Heteroaryl compounds for kinase inhibition | May 13, 2035 | Takeda Pharms Usa |
| Exkivity | US9796712 | Heteroaryl compounds for kinase inhibition | May 13, 2035 | Takeda Pharms Usa |
Mobocertinib Succinate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List